Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 2,256

Document Document Title
WO/1994/014426A1
The invention relates to microfluidised particles of atovaquone and to a method of preparing them. More particularly, the invention is concerned with a pharmaceutical composition containing microfluidised particles of atovaquone which ha...  
WO/1994/012458A1
A saintopin E derivative represented by general formula (I) and useful as an antibacterial and antitumor agent, wherein when R1 represents hydrogen, then R2 represents SO2OH (in the case of UCE1022), while when R1 represents acetyl, then...  
WO/1993/024650A1
The present invention relates generally to therapeutic compositions comprising one or more redox compounds. The therapeutic compositions of the present invention are useful in enhancing cellular ATP production thereby ameliorating the ef...  
WO/1993/015607A1
Ion pairs of hypericin and its analogues and derivatives are prepared by acidifying hypericin to its free acid form and reacting with a predetermined quantity of an organic or inorganic base at a pH below about 11.5. The compounds are us...  
WO/1993/008797A1
T cell-mediated diseases in mammals are treated using compositions comprising a polycyclic aromatic compound, preferably hypericin, pseudohypericin, and isomers, analogs, derivatives, salts, or ion pairs of hypericin or pseudohypericin. ...  
WO1993002710A3  
WO/1993/002710A2
The present invention provides the use of a persistent aryloxy or arylthio free radicals, other than perhalo radicals, for the manufacture of a contrast medium for use in magnetic resonance imaging. Also provided are magnetic resonance i...  
WO/1993/002711A1
The present invention provides the use of a persistent $g(p)-system free radical for the manufacture of a contrast medium for use in magnetic resonance imaging, wherein the electron delocalising $g(p)-system of said radical comprises at ...  
WO/1992/012114A1
A process for producing an aromatic hydroxy compound by oxidizing directly an aromatic compound with an oxidizing agent, wherein the reaction is conducted in the presence of a catalyst comprising at least one platinum-group metal or its ...  
WO/1992/007814A1
The invention relates to w-(1,4-quinonyl)-alkanals with a -(CH¿2?)¿n?-CHO side chain in the 2nd or 3rd position, wherein n is a whole number from 7 to 15. Process for making them and the use of such or other alkanals as substrates for ...  
WO/1992/001448A1
Ubidecarenone is effective in curing sleep apnea in a dose of 1 to 3,000 mg per day for adult. It is particularly effective to administer 2 to 50 mg thereof before sleep.  
WO/1991/013855A1
A novel phenanthrene derivative of general formula (1), its salt, a compound further derived therefrom, and its salt; a process for the production thereof; and an interleukin 1 (IL-1) inhibitor containing the derivative as the active ing...  
WO/1991/008189A1
Polyhydroxy-1,4-naphthoquinones of general formula (I), where, with R1 = R2 = hydroxy group, R3 = tret.butyl and R4 = hydrogen, or R3 = hydroxy group and R4 = propyl or 2-carboxyethyl; with R1 = R2 = 2-hydroxyethyl group, R3 = hydroxy gr...  
WO/1991/004021A1
The present invention relates to the use of 2-[4-(4-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other physiologically functional derivative thereof for the manufacture of a medicament fo...  
WO/1990/010438A1
Disclosed herein are antiviral agents, pharmaceutical formulations comprising effective amounts of these agents and methods for treating mammals suffering from infections caused by viruses. The agents are analogs, isomers, homologs, deri...  
WO/1990/009974A1
4-Substituted anthracyclinones of general formula (I), wherein R represents a hydrogen atom or a COOR1 group in which R1 may be a hydrogen atom or an optionally substituted C1-C10 alkyl group, which are intermediates in the preparation o...  
WO/1990/008759A1
The present invention concerns compounds of formula (I) wherein R1 is hydrogen, a hydroxy group or a methoxy group; R2 is hydrogen or a methyl group; R3 is hydrogen or a methyl group; Y is a secondary amino group (NHalkyl) or a tertiary ...  
WO/1990/007479A1
A method of obtaining bromated aromatic and heterocyclic combinations containing acceptor groups provides for bromination of aromatic and heterocyclic combinations, containing acceptor groups, with bromine or hydrobromic acid, the proces...  
WO/1990/004601A1
4-substituted anthracyclinones of formula (I), wherein R represents a straight or branched alkyl, alkenyl or alkynyl group of up to 16 carbon atoms optionally substituted by (a) an aryl group which is unsubstituted or substituted by an i...  
WO1989002886A3  
WO/1989/002886A2
The new 2-neopentylanthraquinone compound, which is produced by Friedel-Crafts acylation of neopenthylbenzene with phthalic anhydride followed by cyclization of the 2-(4-neopentylbenzoyl) benzoic acid obtained in the presence of strong a...  
WO/1989/001329A1
Pharmaceutical formulations comprising aromatic polycyclic dione compounds useful for treating mammals suffering from diseases caused by retroviruses are disclosed herein. A method for treating mammals suffering from retrovirus infection...  
WO/1988/008415A1
A method for producing a compound of formula (I) (wherein R1 and R2 each stand for a lower alkyl group; n denotes an integer of 0 to 21; X stands for hydrogen atom or an optionally protected hydroxyl group; and Y stands for an optionally...  
WO1987001698A3  
WO/1987/001698A2
Novel 1,4-naphthalenediol and 1,4-hydroquinone derivatives of formulas (I, II, III and IV) and their therapeutic uses as 5-lipoxygenase inhibitors, leukotriene inhibitors, antiinflammatory and/or inhibitors of mucus secretion agents. Als...  
WO/1986/004503A1
A pharmaceutical composition, comprising: Coenzyme Q10 (ubidecarenone) 2-17% by weight; Lecithin 50-70% by weight; Surfactant agent 20-48% by weight. The surfactant agent has a melting point comprised between 35 and 55oC and a HLB value ...  
WO/1986/004058A1
Quinone derivatives represented by general formula (I), wherein R1 and R2 may be the same or different and each represents hydrogen, methyl or methoxy or, when taken together, R1 and R2 represent -CH=CH-CH=CH-, R3 represents hydrogen or ...  
WO/1986/000887A1
Quinone derivatives represented by general formula (I) wherein R1 and R2 may be the same or different, and each represents hydrogen, methyl or methoxy or, when taken together, R1 and R2 represent -CH=CH-CH=CH-, R3 represents hydrogen or ...  
WO/1985/001726A1
A compound of formula II and tautomeric forms thereof wherein: R1 - R4 are H, alkyl, aryl, alkaryl, halogen, hydroxy, alkoxy, aryloxy, aralkoxy, acyloxy, amino or alkylamino; R8 has the same meaning as given to R1 - R4 or may be glycosyl...  
WO/1984/004300A1
A process for removing unalkylated anthraquinones from alkylated anthraquinone by forming a solution thereof, reducing the solution sufficiently so that at least part of the unalkylated anthraquinone is in the reduced form and extracting...  
WO/1982/003625A1
An inactivation of the catalytic system easily occurs during the oxidation of reactive aromatics by means of molecular oxygen, in a carboxylic acid solution and in presence of a catalyst which, consists itself of a cobalt compound with o...  
WO/1981/002797A1
Phenolic and naphtholic compounds have been found to be useful as dye forming developers in photographic silver halide constructions. The dye forming developers form dye images upon oxidation and do not require the presence of couplers i...  
WO/1981/002574A1
1, 4-naphthoquinone derivatives represented by the following general formula: (FORMULA) (wherein R1 represents a hydrogen atom, a hydroxy group, a lower alkoxy group or an arylthio group, R2 represents a carboxy group, an esterified carb...  
WO/1980/000340A1
In a process for purifying naphthoquinone obtained by gas phase catalytic oxidation of naphthalene, the improvement which comprises contacting a solution of the naphthoquinone dissolved in a solvent capable of dissolving naphthoquinone a...  
JP2016047854A
【課題】ミトコンドリア障害を治療する、1 つ以上のエネルギーバイオマーカーを調節す る、1つ以上のエネルギーバイオマーカーを 正常化する、または1つ以上のエネルギ...  
JP2016509573A
本発明は、in vivoでの薬物動態が改善した、改良され たトコフェリルキノン誘導体およびトコフェ ロール誘導体に関し、いくつかの実施形態に おいて、トコフェリル...  
JP2016034979A
【課題】ミトコンドリア病の処置のための( ヘテロ)アリール−p−キノン誘導体を提供 すること。【解決手段】ミトコンドリア病、 例えばフリートライヒ運動失調(FRD...  
JP2016029112A
【課題】フリードライヒ失調症;レーバー遺 伝性視神経障害;乳酸アシドーシスと脳卒中 様症状を伴うミトコンドリア脳筋症(MEL AS);およびキーンズセイアー症候群...  
JP5860722B2  
JP2016006043A
【課題】抗トリパノソーマ活性を有する、新 規な化合物の提供。【解決手段】式(1)で 表される化合物又はその薬学的に許容される 塩。(R1はC1〜10のアルコキシ基...  
JP2015533794A
ミトコンドリア障害、エネルギー処理低下障 害、神経変性疾患および老化による疾患を含 めた酸化ストレス障害を処置または抑制する ため、あるいは1種もしくは複数種のエ...  
JP2015193663A
To provide dyeing of keratin materials using two colorless dye precursors, at least one of which contains a disulfide/thiol unit, the precursors reacting together chemically to form the color in situ.The process according to the inventio...  
JP2015531404A
ビタミンK2のMK−7型の調整方法は、「 全トランス」配置のヘキサプレニル鎖を「1 +6」戦略によるメナジオールのモノプレニ ル誘導体に付加することによって特徴づ...  
JP2015187169A
To provide processes for production, enrichment and/or isolation of pure α-tocotrienol.The invention discloses novel processes for production, enrichment and/or isolation of α-tocotrienol from a raw material source comprising at least ...  
JP2015168660A
To produce arylhydroquinones and arylquinones in mild conditions without using a rare metal catalyst.A method for producing arylhydroquinones by Michael addition of a an aryl compound with quinones in the presence of a catalyst. As the c...  
JP2015527322A
抗増殖性作用を、特にがん細胞に対して示す レイン類似体が、本明細書に記載されている 。一部の実施形態では、化合物は、平坦また は平面的環系を含有する。このような環...  
JP5775459B2  
JP5748660B2  
JP5725299B2  
JPWO2013121873A1
本発明のビアリール化合物の製造方法は、テ トラブチルアンモニウムヨージド、及びte rt−ブチルヒドロペルオキシド又は過酸化 水素の存在下、フェノール又はナフトー...  

Matches 251 - 300 out of 2,256